vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Claritev Corp (CTEV). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $139.2M, roughly 1.8× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -32.7%, a 68.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 6.2%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 2.5%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
ADMA vs CTEV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $246.6M |
| Net Profit | $49.4M | $-80.6M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | -3.1% |
| Net Margin | 35.5% | -32.7% |
| Revenue YoY | 18.4% | 6.2% |
| Net Profit YoY | -55.9% | 41.6% |
| EPS (diluted) | $0.20 | $-4.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $246.6M | ||
| Q3 25 | $134.2M | $246.0M | ||
| Q2 25 | $122.0M | $241.6M | ||
| Q1 25 | $114.8M | $231.3M | ||
| Q4 24 | $117.5M | $232.1M | ||
| Q3 24 | $119.8M | $230.5M | ||
| Q2 24 | $107.2M | $233.5M | ||
| Q1 24 | $81.9M | $234.5M |
| Q4 25 | $49.4M | $-80.6M | ||
| Q3 25 | $36.4M | $-69.8M | ||
| Q2 25 | $34.2M | $-62.6M | ||
| Q1 25 | $26.9M | $-71.3M | ||
| Q4 24 | $111.9M | $-138.0M | ||
| Q3 24 | $35.9M | $-391.4M | ||
| Q2 24 | $32.1M | $-576.7M | ||
| Q1 24 | $17.8M | $-539.7M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | -3.1% | ||
| Q3 25 | 38.0% | 4.1% | ||
| Q2 25 | 35.1% | 6.9% | ||
| Q1 25 | 30.4% | 4.2% | ||
| Q4 24 | 32.6% | -17.8% | ||
| Q3 24 | 33.1% | -146.7% | ||
| Q2 24 | 36.6% | -224.4% | ||
| Q1 24 | 26.7% | -207.4% |
| Q4 25 | 35.5% | -32.7% | ||
| Q3 25 | 27.1% | -28.4% | ||
| Q2 25 | 28.1% | -25.9% | ||
| Q1 25 | 23.4% | -30.8% | ||
| Q4 24 | 95.2% | -59.4% | ||
| Q3 24 | 30.0% | -169.8% | ||
| Q2 24 | 29.9% | -247.0% | ||
| Q1 24 | 21.7% | -230.1% |
| Q4 25 | $0.20 | $-4.88 | ||
| Q3 25 | $0.15 | $-4.23 | ||
| Q2 25 | $0.14 | $-3.81 | ||
| Q1 25 | $0.11 | $-4.38 | ||
| Q4 24 | $0.45 | $-8.49 | ||
| Q3 24 | $0.15 | $-24.25 | ||
| Q2 24 | $0.13 | $-35.78 | ||
| Q1 24 | $0.08 | $-33.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $16.8M |
| Total DebtLower is stronger | $72.1M | $4.6B |
| Stockholders' EquityBook value | $477.3M | $-173.9M |
| Total Assets | $624.2M | $4.9B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $16.8M | ||
| Q3 25 | $61.4M | $39.2M | ||
| Q2 25 | $90.3M | $56.4M | ||
| Q1 25 | $71.6M | $23.1M | ||
| Q4 24 | $103.1M | $16.8M | ||
| Q3 24 | $86.7M | $86.6M | ||
| Q2 24 | $88.2M | $48.8M | ||
| Q1 24 | $45.3M | $58.7M |
| Q4 25 | $72.1M | $4.6B | ||
| Q3 25 | $72.4M | $4.5B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | $72.3M | $4.5B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $4.5B |
| Q4 25 | $477.3M | $-173.9M | ||
| Q3 25 | $431.2M | $-101.8M | ||
| Q2 25 | $398.3M | $-39.9M | ||
| Q1 25 | $373.4M | $14.8M | ||
| Q4 24 | $349.0M | $84.0M | ||
| Q3 24 | $231.9M | $207.6M | ||
| Q2 24 | $188.3M | $603.4M | ||
| Q1 24 | $153.7M | $1.2B |
| Q4 25 | $624.2M | $4.9B | ||
| Q3 25 | $568.7M | $5.0B | ||
| Q2 25 | $558.4M | $5.1B | ||
| Q1 25 | $510.6M | $5.1B | ||
| Q4 24 | $488.7M | $5.2B | ||
| Q3 24 | $390.6M | $5.3B | ||
| Q2 24 | $376.4M | $5.7B | ||
| Q1 24 | $350.9M | $6.4B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 304.87× | ||
| Q4 24 | 0.21× | 53.67× | ||
| Q3 24 | — | 21.73× | ||
| Q2 24 | — | 7.48× | ||
| Q1 24 | — | 3.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $66.3M |
| Free Cash FlowOCF − Capex | $34.6M | $36.4M |
| FCF MarginFCF / Revenue | 24.8% | 14.8% |
| Capex IntensityCapex / Revenue | 0.8% | 12.1% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-12.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $66.3M | ||
| Q3 25 | $13.3M | $19.9M | ||
| Q2 25 | $21.1M | $61.2M | ||
| Q1 25 | $-19.7M | $-30.1M | ||
| Q4 24 | $50.2M | $-33.4M | ||
| Q3 24 | $25.0M | $72.8M | ||
| Q2 24 | $45.6M | $18.5M | ||
| Q1 24 | $-2.2M | $49.7M |
| Q4 25 | $34.6M | $36.4M | ||
| Q3 25 | $-1.1M | $-16.3M | ||
| Q2 25 | $18.7M | $36.6M | ||
| Q1 25 | $-24.4M | $-68.9M | ||
| Q4 24 | $47.5M | $-63.8M | ||
| Q3 24 | $24.0M | $41.1M | ||
| Q2 24 | $43.6M | $-7.0M | ||
| Q1 24 | $-4.6M | $19.2M |
| Q4 25 | 24.8% | 14.8% | ||
| Q3 25 | -0.8% | -6.6% | ||
| Q2 25 | 15.3% | 15.2% | ||
| Q1 25 | -21.2% | -29.8% | ||
| Q4 24 | 40.4% | -27.5% | ||
| Q3 24 | 20.0% | 17.8% | ||
| Q2 24 | 40.7% | -3.0% | ||
| Q1 24 | -5.6% | 8.2% |
| Q4 25 | 0.8% | 12.1% | ||
| Q3 25 | 10.7% | 14.7% | ||
| Q2 25 | 2.0% | 10.2% | ||
| Q1 25 | 4.1% | 16.8% | ||
| Q4 24 | 2.3% | 13.1% | ||
| Q3 24 | 0.9% | 13.8% | ||
| Q2 24 | 1.9% | 10.9% | ||
| Q1 24 | 2.9% | 13.0% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CTEV
Segment breakdown not available.
